Dr. K. V. Subbareddy Institute of Pharmacy
Pharmacogenomics is an emerging field that combines genetics and pharmacology to understand how genetic variations influence an individual's response to medications. Differences in genes that encode drug-metabolizing enzymes, transporters, and drug targets can significantly affect drug absorption, metabolism, efficacy, and the risk of adverse drug reactions. Traditional pharmacotherapy often follows a “one-size-fits-all” approach, which may lead to variability in treatment outcomes among patients. Pharmacogenomics aims to overcome this limitation by enabling personalized or precision medicine, where drug therapy is tailored according to the patient’s genetic profile. Advancements in genomic technologies and molecular diagnostics have made pharmacogenomic testing more accessible in clinical settings. The application of pharmacogenomics has expanded across several medical specialties, including oncology, cardiology, psychiatry, and infectious diseases. In oncology, genetic profiling helps guide targeted therapies for cancer treatment, while in cardiology and psychiatry, pharmacogenomic testing assists in selecting appropriate drugs and optimizing dosing strategies. By predicting drug response and identifying individuals at risk for adverse drug reactions, pharmacogenomics improves treatment safety and therapeutic effectiveness.
Pharmacogenomics (PGx) is an advanced and rapidly evolving field that combines pharmacology and genomics to understand how genetic variations influence an individual’s response to medications. The primary goal of pharmacogenomics is to optimize drug therapy by tailoring medications and dosages according to a patient’s genetic profile. This personalized approach aims to maximize therapeutic effectiveness while minimizing the risk of adverse drug reactions. By integrating genetic information into clinical decision-making, pharmacogenomics has become a key component of precision medicine, which focuses on delivering the right drug at the right dose to the right patient.
Variations in the human genome can significantly influence how drugs are absorbed, distributed, metabolized, and eliminated from the body. These variations are often caused by genetic polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and drug targets. For example, differences in enzymes such as cytochrome P450 (CYP450) can alter the rate at which drugs are metabolized, resulting in either reduced therapeutic effects or increased drug toxicity. Pharmacogenomics studies these genetic differences to predict individual drug responses and guide clinicians in selecting the most appropriate therapy.
Traditionally, pharmacotherapy has followed a “one-size-fits-all” approach, where patients receive standard medications and doses without considering their genetic background. However, this conventional method often leads to variability in treatment outcomes. Some patients may experience optimal therapeutic benefits, while others may develop severe side effects or show little to no response to the same medication. These differences highlight the importance of understanding genetic factors that influence drug response.
Pharmacogenomics addresses this challenge by bridging the gap between genetics and clinical pharmacology. Through genetic testing, healthcare professionals can identify variations in genes responsible for drug metabolism and action. This information allows clinicians to adjust drug selection and dosage according to the patient’s genetic makeup, thereby improving treatment efficacy and reducing the likelihood of adverse drug reactions. As a result, pharmacogenomics contributes to safer and more effective medication management.
The clinical application of pharmacogenomics has expanded significantly in recent years. It is increasingly used in several medical specialties, including oncology, cardiology, psychiatry, and infectious diseases. In oncology, pharmacogenomic testing helps identify genetic mutations in tumors, enabling the use of targeted therapies that specifically attack cancer cells. In cardiology, genetic testing can guide the use of drugs such as anticoagulants and antiplatelet agents. Similarly, in psychiatry, pharmacogenomics helps determine the most suitable antidepressants or antipsychotics based on individual metabolic profiles.
Advancements in genomic technologies, such as next-generation sequencing and genome-wide association studies, have further accelerated pharmacogenomic research and clinical implementation. In addition, several international organizations have developed clinical guidelines to support the use of pharmacogenomic information in prescribing medications. The integration of pharmacogenomic data into electronic health records is also facilitating its routine use in clinical practice.
Principles of Pharmacogenomics:
Pharmacogenomics focuses on understanding how genetic variations influence an individual’s response to medications. These variations may affect how drugs are processed in the body and how they interact with biological targets. The two fundamental principles that explain these effects are pharmacokinetics and pharmacodynamics. Together, these mechanisms determine the overall therapeutic outcome of a drug. Studying these principles allows healthcare professionals to predict drug response and optimize treatment strategies for individual patients.
Pharmacokinetics refers to the process by which a drug moves through the body and includes four major stages: absorption, distribution, metabolism, and excretion (ADME). Genetic differences among individuals can significantly influence each of these processes. Variations in genes encoding drug-metabolizing enzymes, transport proteins, and metabolic pathways may lead to differences in drug concentration within the body.
One of the most important groups of enzymes involved in drug metabolism is the cytochrome P450 (CYP450) enzyme family. These enzymes are primarily found in the liver and are responsible for metabolizing a large proportion of commonly used medications. Genetic polymorphisms in genes such as CYP2C9, CYP2C19, CYP2D6, and CYP3A5 can result in altered enzyme activity, which in turn affects how quickly or slowly drugs are metabolized.
Based on genetic variations affecting enzyme activity, individuals can be classified into different metabolizer phenotypes. These include poor metabolizers, who have little or no functional enzyme activity, leading to slower drug metabolism and potentially higher drug concentrations in the body. Intermediate metabolizers exhibit reduced enzyme activity compared to normal individuals, resulting in moderately slower drug metabolism.
Pharmacodynamics refers to the biological and physiological effects of drugs on the body, including the mechanisms through which drugs exert their therapeutic actions. This process involves the interaction of drugs with specific biological targets such as receptors, enzymes, ion channels, and signaling proteins. Genetic variations in the genes encoding these targets can influence how effectively a drug produces its intended effect.
Polymorphisms in receptor genes may alter receptor structure, expression, or function, thereby affecting drug binding and response. As a result, some individuals may show reduced drug sensitivity, while others may exhibit increased sensitivity or exaggerated responses. These genetic differences can significantly impact the effectiveness of medications and the likelihood of adverse drug reactions.
For example, variations in genes encoding drug targets can modify the therapeutic response to medications used in cardiovascular diseases, psychiatric disorders, and cancer therapy. In certain cases, genetic differences may lead to treatment failure if the drug cannot effectively interact with its target. Conversely, increased receptor sensitivity may enhance the drug’s effect but also increase the risk of side effects.
Genetic Variants Influencing Drug Response :
Genetic variations play a crucial role in determining how individuals respond to medications. Differences in specific genes can influence drug metabolism, drug transport, and immune responses, ultimately affecting the efficacy and safety of pharmacotherapy. These genetic variations, commonly known as genetic polymorphisms, may lead to differences in therapeutic outcomes among patients receiving the same medication. Understanding these genetic factors is essential for the successful implementation of pharmacogenomics in clinical practice. The major categories of genetic variants influencing drug response include drug-metabolizing enzymes, drug transporters, and immune response genes.
Drug-metabolizing enzymes are responsible for the biotransformation of drugs, mainly in the liver, converting active drugs into inactive metabolites or activating prodrugs into their active forms. Genetic polymorphisms in the genes encoding these enzymes can significantly affect the rate at which drugs are metabolized. Variations in enzyme activity may lead to differences in drug concentration within the body, thereby influencing both therapeutic effectiveness and the risk of adverse drug reactions.
Several pharmacogenes involved in drug metabolism have been extensively studied. Among these, CYP2D6, CYP2C9, and CYP2C19 belong to the cytochrome P450 enzyme family and play a major role in the metabolism of many commonly used medications, including antidepressants, beta-blockers, anticoagulants, and proton pump inhibitors. Genetic variations in these genes may result in reduced, normal, or increased enzyme activity, which in turn affects drug metabolism and patient response.
Another important gene is DPYD (dihydropyrimidine dehydrogenase), which is involved in the metabolism of certain chemotherapy drugs such as fluoropyrimidines. Deficiency in DPYD enzyme activity can lead to severe drug toxicity due to the accumulation of the active drug in the body. Similarly, the TPMT (thiopurine S-methyltransferase) gene plays an important role in the metabolism of thiopurine drugs used in the treatment of leukemia and autoimmune diseases. Individuals with reduced TPMT activity may develop serious bone marrow toxicity when treated with standard doses of these medications.
Drug transporter proteins are responsible for the movement of drugs across biological membranes, influencing drug absorption, distribution, and elimination. These transporters regulate the entry and exit of drugs into cells and tissues, including important organs such as the liver, kidneys, intestines, and brain. Genetic variations in transporter genes can alter the function or expression of these proteins, thereby affecting drug concentration in different parts of the body.
Two important transporter genes involved in pharmacogenomics are ABCB1 (ATP-binding cassette subfamily B member 1) and SLCO1B1 (solute carrier organic anion transporter family member 1B1). The ABCB1 gene encodes P-glycoprotein, a membrane transporter that pumps drugs out of cells and plays a significant role in drug absorption and elimination. Variations in this gene may influence the effectiveness of drugs by altering their availability in target tissues.
The SLCO1B1 gene encodes a transporter responsible for the uptake of certain drugs into liver cells. Genetic variants in SLCO1B1 can affect the hepatic uptake
and metabolism of medications such as statins. Some variants are associated with an increased risk of drug-induced muscle toxicity, particularly in patients taking statin therapy. Understanding these genetic differences helps clinicians select appropriate medications and reduce the risk of adverse effects.
Immune response genes also play an important role in determining an individual’s susceptibility to drug-induced hypersensitivity reactions. Variations in genes involved in immune system regulation can trigger abnormal immune responses to certain medications, leading to severe adverse drug reactions.
Among these genes, human leukocyte antigen (HLA) genes are particularly important. HLA proteins are responsible for presenting foreign antigens to immune cells and initiating immune responses. Certain HLA alleles have been strongly associated with severe drug hypersensitivity reactions. For example, specific HLA variants increase the risk of life-threatening conditions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis when exposed to certain medications.
These immune-mediated reactions are rare but potentially fatal, making genetic screening for high-risk HLA alleles an important step in preventing adverse drug reactions. Pharmacogenomic testing can identify patients who carry these risk alleles and help clinicians avoid prescribing drugs that may trigger severe hypersensitivity.
Clinical Applications of Pharmacogenomics :
Pharmacogenomics has significant clinical applications across multiple medical specialties. By identifying genetic variations that influence drug metabolism, efficacy, and toxicity, pharmacogenomics enables healthcare professionals to select the most appropriate medications and dosages for individual patients. This approach improves therapeutic outcomes, reduces adverse drug reactions, and supports the development of personalized treatment strategies. Some of the most important areas where pharmacogenomics is widely applied include oncology, cardiovascular medicine, psychiatry, and infectious diseases.
Oncology is one of the most advanced and widely studied areas in the field of pharmacogenomics. Cancer is primarily a genetic disease caused by mutations in genes that regulate cell growth and division. Pharmacogenomic testing helps identify specific genetic alterations in tumor cells, allowing clinicians to select targeted therapies that act on these molecular abnormalities.
Several important genes are used as biomarkers to guide cancer treatment. Mutations in genes such as EGFR (Epidermal Growth Factor Receptor), BRAF, BRCA1, KRAS, and ERBB2 (HER2) are commonly analyzed to determine the most effective therapeutic approach. For example, EGFR mutations can predict the response to certain tyrosine kinase inhibitors used in lung cancer treatment. Similarly, mutations in BRCA genes are associated with breast and ovarian cancers and can guide the use of specific targeted drugs such as PARP inhibitors.
Pharmacogenomic testing in oncology not only helps identify patients who are most likely to benefit from a specific therapy but also prevents the use of ineffective treatments. This approach reduces unnecessary toxicity and improves overall survival rates. As a result, pharmacogenomics has become an essential component of precision oncology.
Pharmacogenomics also plays an important role in optimizing drug therapy for cardiovascular diseases. Genetic variations can influence the metabolism and effectiveness of several commonly used cardiovascular medications. Pharmacogenomic testing helps guide the selection and dosing of these drugs, improving safety and treatment outcomes.
One of the most well-known examples is warfarin, an anticoagulant used to prevent blood clots. Variations in genes such as CYP2C9 and VKORC1 affect warfarin metabolism and sensitivity. Patients with certain genetic variants may require lower doses to avoid excessive bleeding, while others may need higher doses to achieve the desired therapeutic effect.
Another important example is clopidogrel, an antiplatelet drug used to prevent heart attacks and strokes. Clopidogrel requires activation by the CYP2C19 enzyme. Individuals with reduced CYP2C19 activity may not effectively convert the drug into its active form, leading to reduced therapeutic effect and increased risk of cardiovascular events.
Pharmacogenomics is also relevant for statins, which are widely used to lower cholesterol levels. Genetic variants in certain transporter genes can increase the risk of statin-induced muscle toxicity. Identifying these genetic differences allows clinicians to adjust drug selection or dosage to minimize adverse effects.
Psychiatric disorders such as depression, anxiety, and schizophrenia are often treated with medications that show significant variability in patient response. Pharmacogenomics helps explain why some patients respond well to certain psychiatric medications while others experience side effects or lack of therapeutic benefit.
Genetic variations in drug-metabolizing enzymes, particularly CYP2D6 and CYP2C19, influence the metabolism of many antidepressants, antipsychotics, and mood stabilizers. Individuals with reduced enzyme activity may accumulate higher drug concentrations, increasing the risk of adverse effects. On the other hand, ultra-rapid metabolizers may eliminate drugs too quickly, resulting in reduced therapeutic response.
Pharmacogenomic testing can help clinicians select medications that are better suited to a patient’s genetic profile. This approach improves treatment effectiveness, reduces trial-and-error prescribing, and enhances patient adherence to therapy.
Pharmacogenomics is increasingly being applied in the treatment of infectious diseases to improve drug safety and effectiveness. Genetic variations can influence how individuals respond to antiviral drugs, antibiotics, and other antimicrobial agents.
In certain viral infections, pharmacogenomic testing can help identify patients who are more likely to respond to specific antiviral therapies. For example, genetic differences in drug metabolism enzymes may affect the effectiveness or toxicity of antiviral medications used in diseases such as HIV, hepatitis, and influenza.
Pharmacogenomics can also help prevent severe adverse drug reactions associated with certain antimicrobial drugs. By identifying patients with genetic susceptibility to drug toxicity, healthcare providers can modify treatment strategies and select safer alternatives.
Benefits of Pharmacogenomics in Clinical Practice :
The integration of pharmacogenomics into clinical practice offers numerous advantages for both healthcare providers and patients. By incorporating genetic information into the process of drug selection and dosing, pharmacogenomics allows clinicians to design treatment strategies that are tailored to the individual characteristics of each patient. This approach represents a major shift from traditional treatment methods toward personalized and precision medicine, ultimately improving the safety and effectiveness of pharmacotherapy.
One of the most important benefits of pharmacogenomics is personalized drug therapy. Genetic variations among individuals can significantly influence how they respond to medications. Pharmacogenomic testing helps identify these genetic differences, enabling clinicians to select medications that are most suitable for a patient’s genetic profile. As a result, treatment plans can be customized to achieve optimal therapeutic outcomes.
Another key advantage is the improvement of drug efficacy. Some patients may not respond adequately to standard medications due to genetic differences that affect drug metabolism or drug targets. Pharmacogenomic information helps predict how well a patient will respond to a particular medication, allowing healthcare professionals to choose drugs that are more likely to be effective. This reduces the likelihood of treatment failure and improves overall patient outcomes.
Pharmacogenomics also plays a significant role in reducing adverse drug reactions (ADRs). Adverse drug reactions are a major cause of hospitalization and morbidity worldwide. Genetic variations in drug-metabolizing enzymes and immune-related genes can increase the risk of drug toxicity or hypersensitivity reactions. By identifying patients who are genetically predisposed to such reactions, pharmacogenomic testing allows clinicians to avoid high-risk medications or adjust drug doses appropriately.
Another important benefit is better drug selection and dosing. Genetic information can guide clinicians in determining the most appropriate dose of a medication for each patient. For example, individuals with reduced drug metabolism may require lower doses to prevent toxicity, while those with faster metabolism may need higher doses to achieve therapeutic effects. This individualized dosing strategy helps maintain optimal drug concentrations in the body and enhances treatment safety.
Pharmacogenomics can also contribute to cost-effective treatment strategies. Although genetic testing may initially increase healthcare costs, it can reduce overall expenses in the long term by preventing ineffective treatments, avoiding adverse drug reactions, and minimizing hospitalizations. By selecting the most appropriate therapy from the beginning, pharmacogenomics reduces the need for repeated treatment trials and additional medical interventions.
In addition to these clinical benefits, pharmacogenomic information is increasingly being incorporated into drug labels and clinical guidelines. Regulatory authorities and healthcare organizations now recommend pharmacogenomic testing for certain medications to improve treatment safety and effectiveness. These guidelines provide clinicians with evidence-based recommendations on how to use genetic information in drug prescribing.
Furthermore, pharmacogenomics supports the advancement of precision medicine, where healthcare decisions are based on a patient’s genetic, environmental, and lifestyle factors. The integration of pharmacogenomic data into electronic health records and clinical decision support systems is also helping healthcare providers access and apply genetic information more efficiently in routine clinical practice.
Challenges in Implementing Pharmacogenomics :
Although pharmacogenomics has great potential to improve drug therapy and support personalized medicine, several challenges still limit its widespread implementation in routine clinical practice. These barriers include economic, educational, ethical, and regulatory issues that affect the adoption of pharmacogenomic testing in healthcare systems. Addressing these challenges is essential for the successful integration of pharmacogenomics into modern medical practice.
One of the major challenges in implementing pharmacogenomics is the high cost of genetic testing and required infrastructure. Pharmacogenomic testing often involves advanced molecular diagnostic techniques such as DNA sequencing and genotyping, which require specialized laboratory equipment and trained personnel. Many healthcare institutions, particularly in developing countries, may lack the necessary laboratory facilities and technical expertise to perform these tests. In addition, the cost of pharmacogenomic testing may not always be covered by health insurance systems, making it difficult for many patients to access these services. The high cost can limit routine use in clinical practice, especially in resource-limited healthcare settings.
Another important barrier is the limited awareness and education among healthcare professionals regarding pharmacogenomics. Many physicians, pharmacists, and other healthcare providers may not have sufficient training to understand genetic test results or apply pharmacogenomic information in clinical decision-making. Pharmacogenomics is a relatively new and rapidly evolving field, and its integration into medical and pharmacy education is still developing. Without proper knowledge and training, healthcare providers may hesitate to incorporate genetic testing into their prescribing practices.
The use of genetic information in healthcare also raises ethical, legal, and privacy concerns. Genetic data are highly sensitive and personal, and there is a risk that such information could be misused or disclosed without proper consent. Protecting patient confidentiality and ensuring the secure storage of genetic information are critical considerations in pharmacogenomic testing. There are also concerns related to genetic discrimination, where individuals may face unfair treatment by employers or insurance companies based on their genetic information. To address these issues, strong ethical guidelines and legal frameworks are required to regulate the collection, storage, and use of genetic data while safeguarding patient rights.
Although several international organizations have developed pharmacogenomic guidelines, standardization and consistent implementation across healthcare systems remain challenging. Different countries and healthcare institutions may follow different recommendations, leading to variations in clinical practice. In some cases, clinicians may find it difficult to interpret pharmacogenomic test results due to the lack of clear and universally accepted guidelines. Additionally, integrating pharmacogenomic information into clinical workflows and electronic health records requires coordinated efforts among healthcare providers, laboratories, and regulatory agencies.
Role of Healthcare Professionals in Pharmacogenomics :
Healthcare professionals play a vital role in the successful implementation of pharmacogenomics in clinical practice. The effective use of pharmacogenomic information requires collaboration among physicians, pharmacists, genetic specialists, laboratory scientists, and other healthcare providers. Each professional contributes unique expertise to ensure that genetic data are accurately interpreted and appropriately applied to optimize patient care.
Physicians are responsible for identifying patients who may benefit from pharmacogenomic testing and incorporating genetic information into clinical decision-making. They evaluate the patient’s medical history, disease condition, and medication profile to determine whether pharmacogenomic testing is necessary. Based on test results, physicians can adjust drug selection, dosing, or treatment strategies to improve therapeutic outcomes and reduce the risk of adverse drug reactions.
Clinical pharmacists play an especially important role in the application of pharmacogenomics. Because of their expertise in pharmacology and medication therapy management, pharmacists are well-positioned to interpret pharmacogenomic test results and recommend appropriate medication adjustments. They analyze how genetic variations influence drug metabolism, efficacy, and toxicity, and then provide guidance on drug selection and dosage modifications.
Pharmacists also contribute to patient counseling and education regarding pharmacogenomic testing and personalized drug therapy. They help patients understand the purpose of genetic testing, the meaning of test results, and how these results may affect their medication regimen. This communication is essential for improving patient understanding, adherence to therapy, and overall treatment success.
Genetic specialists, including genetic counselors and molecular geneticists, provide expertise in genetic testing, interpretation of genetic data, and counseling patients about genetic risks. They help explain complex genetic information to both healthcare providers and patients, ensuring that pharmacogenomic results are interpreted accurately and ethically.
Laboratory professionals are responsible for performing genetic testing and ensuring the accuracy and reliability of test results. They use advanced molecular diagnostic techniques to identify genetic variants that may influence drug response. High-quality laboratory practices and standardized testing procedures are essential for producing reliable pharmacogenomic data.
Interdisciplinary collaboration among healthcare professionals is essential for integrating pharmacogenomics into routine patient care. Effective communication between physicians, pharmacists, genetic counselors, and laboratory personnel ensures that pharmacogenomic information is properly interpreted and applied in clinical settings.
Healthcare professionals also play an important role in advancing pharmacogenomic research and clinical implementation. By participating in clinical studies, developing treatment guidelines, and educating other healthcare providers, they contribute to the broader adoption of pharmacogenomics in healthcare systems.
In addition, ongoing professional education and training are necessary for healthcare providers to stay updated on the latest developments in pharmacogenomics. Continuous learning helps clinicians understand emerging genetic discoveries, new pharmacogenomic guidelines, and evolving technologies used in genetic testing.
Future Perspectives of Pharmacogenomics :
The future of pharmacogenomics is closely connected with rapid advancements in genomic technologies, bioinformatics, and digital healthcare systems. As scientific research continues to uncover new genetic variants associated with drug response, pharmacogenomics is expected to play an increasingly important role in modern medical practice. The integration of genomic data into healthcare systems will help clinicians make more informed decisions about drug therapy and move toward a more personalized approach to treatment.
One promising development in this field is the use of pre-emptive genetic testing. In this approach, a patient’s genetic profile is determined before the need for medication arises. The genetic information is then stored in electronic health records so that healthcare providers can easily access it when prescribing drugs. This strategy allows clinicians to select appropriate medications and doses based on the patient’s genetic characteristics, reducing the risk of adverse drug reactions and improving therapeutic outcomes.
Another important advancement is the increasing use of whole genome sequencing and next-generation sequencing technologies. These technologies enable researchers and clinicians to analyze large portions of the human genome quickly and accurately. By identifying genetic variants that influence drug metabolism and drug response, whole genome sequencing can help predict how patients will respond to specific medications. As the cost of sequencing continues to decrease, this technology is expected to become more widely used in clinical practice.
The application of artificial intelligence (AI) and machine learning is also transforming the field of pharmacogenomics. AI-based systems can analyze complex genetic data along with clinical information to identify patterns that may influence drug response. These advanced computational tools can assist healthcare professionals in selecting the most appropriate medications and optimizing drug dosing for individual patients. AI-driven decision support systems may soon become an important part of clinical workflows, helping clinicians interpret pharmacogenomic data more efficiently.
Another emerging area is the development of pharmacogenomic decision support systems integrated into electronic health records (EHRs). These systems can automatically alert clinicians when a patient’s genetic profile suggests a potential drug interaction or increased risk of adverse effects. By providing real-time guidance during prescribing, such systems can improve medication safety and support evidence-based clinical decisions.
Population-specific pharmacogenomic research is also gaining attention. Genetic variations that influence drug response may differ among different ethnic and geographic populations. Developing population-specific pharmacogenomic databases helps researchers understand these variations and design treatment guidelines that are more suitable for specific populations. This approach is particularly important for improving drug therapy in diverse populations around the world.
In addition, pharmacogenomics is expected to contribute significantly to the advancement of precision medicine and targeted therapies, especially in fields such as oncology, cardiology, and infectious diseases. As more genetic biomarkers are discovered, new drugs can be developed to specifically target molecular pathways associated with disease.
Despite current challenges, ongoing research, improved genomic technologies, and growing awareness among healthcare professionals are likely to accelerate the integration of pharmacogenomics into routine healthcare. In the future, pharmacogenomic testing may become a standard component of patient care, helping clinicians deliver safer, more effective, and individualized treatment strategies.
CONCLUSION
Pharmacogenomics represents a crucial bridge between genetics and pharmacotherapy, enabling personalized drug therapy based on genetic profiles. By identifying genetic factors influencing drug metabolism, efficacy, and toxicity, pharmacogenomics improves treatment outcomes and reduces adverse reactions. Although challenges such as cost, limited awareness, and ethical concerns remain, ongoing advancements in genomic technology and clinical guidelines are accelerating its integration into healthcare systems. Ultimately, pharmacogenomics has the potential to transform modern clinical practice by promoting safer, more effective, and individualized pharmacotherapy.
REFERENCES
Shaik Ayesha Jabeen, S. Kusuma Kumari, Bridging Genetics and Pharmacotherapy: Pharmacogenomics in Modern Clinical Practice, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 3193-3204. https://doi.org/10.5281/zenodo.19673449
10.5281/zenodo.19673449
